📣 VC round data is live. Check it out!
- Public Comps
- Kaken Pharmaceutical
Kaken Pharmaceutical Valuation Multiples
Discover Kaken Pharmaceutical's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Center Laboratories, AprilBio, Chengdu Kanghua, SPIMACO - ADDWAEIH and more.
Kaken Pharmaceutical Overview
About Kaken Pharmaceutical
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Founded
1948
HQ

Employees
1.6K
Website
Financials (LTM)
EV
$662M
Valuation Multiples
Start free trialKaken Pharmaceutical Financials
Kaken Pharmaceutical reported last 12-month revenue of $482M and EBITDA of $10M.
In the same LTM period, Kaken Pharmaceutical generated $10M in EBITDA and $13M in net income.
Revenue (LTM)
Kaken Pharmaceutical P&L
In the most recent fiscal year, Kaken Pharmaceutical reported revenue of $590M and EBITDA of $138M.
Kaken Pharmaceutical is profitable as of last fiscal year, with gross margin of 62%, EBITDA margin of 23%, and net margin of 15%.
Financial data powered by Morningstar, Inc.
Kaken Pharmaceutical Stock Performance
Kaken Pharmaceutical has current market cap of $926M, and enterprise value of $662M.
Market Cap Evolution
Kaken Pharmaceutical's stock price is $24.44.
Kaken Pharmaceutical share price decreased by 2.2% in the last 30 days, and increased by 1.7% in the last year.
Kaken Pharmaceutical has an EPS (earnings per share) of $2.31.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $662M | $926M | -2.2% | -2.2% | -6.2% | 1.7% | $2.31 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKaken Pharmaceutical Valuation Multiples
Kaken Pharmaceutical trades at 1.4x EV/Revenue multiple, and 68.7x EV/EBITDA.
EV / Revenue (LTM)
Kaken Pharmaceutical Financial Valuation Multiples
As of June 2, 2026, Kaken Pharmaceutical has market cap of $926M and EV of $662M.
Kaken Pharmaceutical has a P/E ratio of 71.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kaken Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Kaken Pharmaceutical Margins & Growth Rates
Kaken Pharmaceutical decreased revenue by 18% and EBITDA by 94% in the last fiscal year.
In the most recent fiscal year, Kaken Pharmaceutical reported gross margin of 62%, EBITDA margin of 23%, and net margin of 15%.
Kaken Pharmaceutical Margins
Kaken Pharmaceutical Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Kaken Pharmaceutical Operational KPIs
Kaken Pharmaceutical's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Kaken Pharmaceutical's Rule of 40 is (5%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kaken Pharmaceutical's Rule of X is (17%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Kaken Pharmaceutical Competitors
Kaken Pharmaceutical competitors include Center Laboratories, AprilBio, Chengdu Kanghua, SPIMACO - ADDWAEIH, Lexicon Pharmaceuticals, ORIC Pharmaceuticals, Jade Biosciences, Annexon, Keqian Biology and ARS Pharmaceuticals.
Most Kaken Pharmaceutical public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 21.7x | - | 2.7x | - | |||
| 123.7x | 119.3x | 519.3x | 367.5x | |||
| 4.5x | 4.3x | 15.3x | 14.6x | |||
| 2.6x | 2.5x | 17.3x | 11.5x | |||
| 16.2x | 18.0x | (19.5x) | (14.5x) | |||
| - | - | (4.6x) | (4.3x) | |||
| - | - | (5.3x) | - | |||
| - | - | (3.3x) | (3.4x) | |||
This data is available for Pro users. Sign up to see all Kaken Pharmaceutical competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Kaken Pharmaceutical
Kaken Pharmaceutical has acquired 2 companies to date.
Last acquisition by Kaken Pharmaceutical was on December 19th 2024. Kaken Pharmaceutical acquired FYARRO for $103M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Kaken Pharmaceutical
| Description | - | ARTham Therapeutics is a clinical-stage biotechnology company headquartered in San Diego that develops disease-modifying therapies for osteoarthritis and other musculoskeletal disorders. Its lead candidate, ARTham-001, targets Wnt signaling pathways to regenerate cartilage in knee osteoarthritis patients. Operating a virtual R&D model, the firm collaborates with academic institutions like the University of California and partners with contract research organizations for preclinical and Phase 1 trials initiated in 2022. ARTham Therapeutics raised Series A funding in 2021 to advance its pipeline toward Phase 2 studies. |
| HQ Country | - | |
| HQ City | - | Yokohama |
| Deal Date | 19 Dec 2024 | 30 Nov 2021 |
| Valuation | $103M | $69M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Kaken Pharmaceutical acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kaken Pharmaceutical
| When was Kaken Pharmaceutical founded? | Kaken Pharmaceutical was founded in 1948. |
| Where is Kaken Pharmaceutical headquartered? | Kaken Pharmaceutical is headquartered in Japan. |
| How many employees does Kaken Pharmaceutical have? | As of today, Kaken Pharmaceutical has over 1K employees. |
| Is Kaken Pharmaceutical publicly listed? | Yes, Kaken Pharmaceutical is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Kaken Pharmaceutical? | Kaken Pharmaceutical trades under 4521 ticker. |
| When did Kaken Pharmaceutical go public? | Kaken Pharmaceutical went public in 1961. |
| Who are competitors of Kaken Pharmaceutical? | Kaken Pharmaceutical main competitors include Center Laboratories, AprilBio, Chengdu Kanghua, SPIMACO - ADDWAEIH, Lexicon Pharmaceuticals, ORIC Pharmaceuticals, Jade Biosciences, Annexon, Keqian Biology, ARS Pharmaceuticals. |
| What is the current market cap of Kaken Pharmaceutical? | Kaken Pharmaceutical's current market cap is $926M. |
| What is the current revenue of Kaken Pharmaceutical? | Kaken Pharmaceutical's last 12 months revenue is $482M. |
| What is the current revenue growth of Kaken Pharmaceutical? | Kaken Pharmaceutical revenue growth (NTM/LTM) is (3%). |
| What is the current EV/Revenue multiple of Kaken Pharmaceutical? | Current revenue multiple of Kaken Pharmaceutical is 1.4x. |
| What is the current EBITDA of Kaken Pharmaceutical? | Kaken Pharmaceutical's last 12 months EBITDA is $10M. |
| What is Kaken Pharmaceutical's EBITDA margin? | Kaken Pharmaceutical's last 12 months EBITDA margin is 2%. |
| What is the current EV/EBITDA multiple of Kaken Pharmaceutical? | Current EBITDA multiple of Kaken Pharmaceutical is 68.7x. |
| How many companies Kaken Pharmaceutical has acquired to date? | As of June 2026, Kaken Pharmaceutical has acquired 2 companies. |
| What was the largest acquisition by Kaken Pharmaceutical? | $103M acquisition of FYARRO on 19th December 2024 was the largest M&A Kaken Pharmaceutical has done to date. |
| What companies Kaken Pharmaceutical acquired? | Kaken Pharmaceutical acquired FYARRO and ARTham Therapeutics. |
| In how many companies Kaken Pharmaceutical has invested to date? | Kaken Pharmaceutical hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Kaken Pharmaceutical
Lists including Kaken Pharmaceutical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
